TARS Tarsus Pharmaceuticals, Inc. Insider Trading

TARS COO Seshadri sells 11,324 shares across 3 days (Mar 17-19) for $772,443.60; stock down 19.1% from 52-week high

Neervannan Seshadri, Chief Operating Officer, executed three separate sales totaling 11,324 shares for $772,443.60 between March 17-19, 2026, at prices ranging from $67.00 to $69.42. This represents an 11.7% reduction in his post-transaction holdings of 85,780 shares. The timing coincides with a period when the stock has declined 19.1% from its 52-week high of $82.51, though it has gained 6.3% over the prior 30 days. Tarsus Pharmaceuticals remains unprofitable (net income of $-12.6M in the latest quarter), though revenue growth has been robust at 146.7% year-over-year. The multiple sales over consecutive business days and the moderate reduction in holdings provide limited signals regarding insider conviction, as the scale of the reduction and the transaction structure do not clearly indicate either concern or confidence.

General Counsel Wahl Bryan sold 12,440 shares of TARS over 3 days at $68.36 avg price, reducing holdings by 16.3% to 64.0K shares

Bryan conducted 3 separate sales totaling 12,440 shares for $850,417.03 on consecutive trading days (March 17-19, 2026) at prices ranging from $67.00 to $69.42. The sales represent a 16.3% reduction in his pre-transaction holdings of 76,399 shares. TARS is a high-growth company (annual revenue growth of 146.7%) but remains unprofitable with recent quarter net income of $-12,585,000.00 against quarterly revenue of $118,697,000.00. The transaction occurred when the stock was trading -19.1% from its 52-week high of $82.51, while the company's market cap stands at $2,840,712,591.00. This substantial equity reduction by a General Counsel warrants attention in the context of ongoing operational losses and prior peak valuations.

CHRO Whitfield sells 12,274 shares over 3 days for $839,069.59; prior same-ticker sales show consistent 30-day declines (-8.0% to -22.2%)

Dianne C. Whitfield, Chief Human Resources Officer at Tarsus Pharmaceuticals (TARS), executed 3 separate sales totaling 12,274 shares for $839,069.59 between March 17–19, 2026, at prices ranging from $67.00 to $69.42 (blended $68.36). This represented a 25.9% reduction in her holdings from 47,302 to 35,028 shares. The current stock price is $66.75, already below the sales prices and down 18.0% over 90 days, while the company remains unprofitable with negative $12.6M net income despite strong 146.7% annual revenue growth. Her prior 5 sales at TARS (since December 16, 2025) all showed negative 30-day returns, ranging from -8.0% to -22.2%, establishing a consistent pattern at this ticker. Cross-ticker, her track record shows a 100.00% well-timed sell rate (90-day metric), though the small prior sample size and the company's current unprofitability suggest investors should monitor whether this latest tranche follows the same post-sale decline pattern evident in her recent activity at TARS.

Tarsus CEO Azamian sells 34,603 shares over 3 days for $2.4M at $68.34 avg, cutting stake 50.9%; stock currently $66.75.

Azamian Bobak R., President/CEO and Board Chair, executed 3 separate sales totaling 34,603 shares for $2,364,903.81 at a blended average price of $68.34 on March 17–19, 2026, reducing his holdings by 50.9% from 68,024 shares to 33,421 shares post-transaction. The filing warrants attention because the CEO liquidated exactly half his stake during a period when the stock is down 18.0% over 90 days and remains 19.1% below its 52-week high of $82.51, despite a recent 30-day bounce of 6.3%. At the company level, Tarsus is unprofitable (full-year net income was negative, latest quarter shows $-12,585,000) but growing revenue aggressively at 146.7% year-over-year, suggesting execution risk in a growth-stage business. His prior 5 sales at TARS show mixed timing outcomes: 3 of the 5 were well-timed at the 90-day mark, including two consecutive December 2023 sales each showing 90-day gains exceeding +54%, though his most recent March 2025 sale declined 18.0% over 90 days, a near-identical pattern to the current period's 90-day drawdown.

COO Seshadri sold 8,366 TARS shares at $76.67; holds 70,817 post-sale as stock trades 9.2% below 52-week high

Neervannan Seshadri, Chief Operating Officer, sold 8,366 shares for $641,421.22, reducing his holdings by 10.6% to 70,817 shares. The sale occurred at $76.67 per share, while the stock now trades at $74.90—2.2% below the transaction price and 9.2% below its 52-week high of $82.51. The company remains unprofitable with net income of $-12,585,000.00 in its most recent fiscal year, despite strong revenue growth of 146.7% year-over-year. The timing of this sale—following a +12.0% 30-day gain but occurring when the stock is materially below its recent peak—coincides with the stock's pullback from elevated levels, warranting investor attention to whether management-level liquidity events presage broader confidence shifts.

CHRO Whitfield sells 15,565 shares at $80.67 avg ($1.3M); reduces stake 40% to 23,393 shares

Whitfield Dianne C., Chief Human Resources Officer at Tarsus Pharmaceuticals, executed 4 separate sales on 2026-01-02 totaling 15,565 shares for $1,255,683.96, reducing her holdings by 40% from 38,958 to 23,393 shares. The blended average sale price of $80.67 sits slightly above the current price of $79.88, near the 52-week high of $82.51. Notably, the company generated $118,697,000.00 in revenue last quarter with annual revenue growth of +948.6%, yet reported a net loss of $-12,585,000.00 and remains unprofitable on a full-year basis. The prior sell at this ticker (2025-12-16) occurred 17 days before this filing, and the insider's overall cross-ticker track record shows only 1 prior sell, providing limited pattern history for contextual assessment.

CHRO Whitfield sold 7,397 shares ($592.5K) at $80.10; holds 38,958 shares post-sale in unprofitable biotech.

Whitfield Dianne C., Chief Human Resources Officer, sold 7,397 shares (39% of holdings pre-transaction) at $80.10 on 2025-12-16, reducing her stake from 46,355 to 38,958 shares. The transaction occurred near the 52-week high of $82.23, just -5.8% below peak valuation in a company trading at $77.48 today. Despite exceptional annual revenue growth of +948.6% and a $3.3B market cap, Tarsus Pharmaceuticals posted negative net income of $-12.6M in its most recent quarter and remains unprofitable on a full-year basis, highlighting execution risk in a hypergrowth phase. The CHRO's material reduction in personal exposure warrants monitoring given the company's profitability challenges and the execution demands of integrating such rapid revenue expansion.

Director William J Link sold 22.9K shares (complete exit) for $1.9M at $81.26 avg; stock now $77.77

Director William J Link executed five separate sales on 2025-12-15 totaling 22,946 shares for $1,864,677.82, liquidating his entire position (from 22.9K shares to zero). The sales were executed across a narrow band ($80.71–$82.39), with a blended average of $81.26, close to the 52-week high of $82.23. At his prior TARS transaction (2025-09-08), a similar sell generated positive 90-day returns (+43.5%), suggesting the earlier sale preceded a period of price strength rather than decline. The company remains unprofitable (net income $-12.6M) despite strong revenue growth of +948.6% year-over-year, signaling a development-stage biotech with elevated risk. A complete insider liquidation of this magnitude warrants investor scrutiny of the director's forward confidence in the company's execution and near-term milestones.

Director Link sold 27.1K shares of TARS at $57.00; stock now $54.33. Holds 143.3K post-sale.

Link, a director at the unprofitable biopharmaceutical firm, sold 27,116 shares at $57.00 on 2025-09-08, reducing his stake by 15.9% to 143,332 shares. The stock has since declined to $54.33, placing the sale near the 52-week high of $58.85 and representing the upper end of recent momentum—the stock is up 32.7% over 90 days and 8.5% over 30 days. Link's prior open-market sales across all tickers showed a 90-day well-timed rate of 0.00%, indicating his historical sells have occurred before subsequent stock increases rather than declines. Against this backdrop of recent acceleration and the company's negative net income of $-20,340,000 in the latest quarter, the timing and magnitude of this reduction warrant monitoring, though a material stake of 143.3K shares remains.

TARS CEO Azamian sold 24,216 shares for $1,163,050.13 across 3 days (Mar 18-20) at blended avg $48.03; reduces stake by 31.1%

CEO Bobak Azamian conducted 3 separate sales totaling 24,216 shares for $1,163,050.13 across March 18–20, reducing his holdings from 77.9K to 53.6K shares (a 31.1% reduction). The transactions occurred at prices ranging from $46.29 to $50.11, with a blended average of $48.03, in a stock currently trading at $49.91 (within the 52-week range of $21.54–$56.94). Notably, his prior trades at TARS showed mixed results: two December 2023 sells generated +17.6% and +15.3% gains over 30 days (and +57.9%, +54.8% over 90 days), while two July 2023 sells resulted in -11.2% to -14.6% declines. The company reports $48.1M in latest-quarter revenue with $-23.4M net income and remains unprofitable, though annual revenue growth stands at +948.6%. The timing pattern across his TARS history suggests inconsistent execution, and this substantial stake reduction warrants monitoring given the company's unprofitable state and the magnitude of the selloff relative to his pre-transaction position.